United Laboratories clears 2026 AGM with 100 % approval of all resolutions; RMB0.26 final dividend sanctioned

Bulletin Express06-23 22:44

The United Laboratories International Holdings Limited (United Laboratories) reported unanimous shareholder approval of every item on the agenda at its Annual General Meeting held on 23 June 2026. Voting was conducted by poll, with 1.01 billion shares—representing 51.09 % of the 1.97 billion issued shares—cast on each resolution. Key outcomes are as follows:

1. Financial Statements & Auditor’s Report Shareholders endorsed the audited consolidated financial statements and the directors’ and auditor’s reports for the year ended 31 December 2025, securing 99.87 % of votes in favour.

2. Dividend Declaration A final dividend of RMB0.26 per share for FY 2025 was approved with virtually unanimous support (99.999 % votes in favour), reaffirming the company’s commitment to shareholder returns.

3. Board Composition & Remuneration • Executive Directors Re-elections: – Mr Tsoi Hoi Shan: 99.14 % support – Ms Zou Xian Hong: 94.36 % support • Independent Non-Executive Director Re-election: – Mr Chong Peng Oon: 93.99 % support • Directors’ remuneration mandate passed with 99.97 % approval.

4. Auditor Re-appointment Deloitte Touche Tohmatsu was re-appointed as auditor, receiving 93.48 % affirmative votes; the Board is authorised to set remuneration.

5. Capital Mandates • Issuance Mandate: Directors gained authority to issue and allot securities up to 20 % of issued share capital, backed by 88.31 % of votes. • Share Repurchase Mandate: Near-unanimous 99.99 % support authorised the Board to repurchase up to 10 % of issued shares. • Extension Mandate: An 88.50 % majority approved extending the issue mandate by the amount of repurchased shares.

Administrative Details All directors attended the meeting in person or electronically. Computershare Hong Kong Investor Services Limited acted as scrutineer. BOCI Trustee (Hong Kong) Limited, holding 0.22 million unvested award shares, abstained from voting in accordance with Listing Rules.

The smooth passage of every resolution, especially the dividend payout and refreshed capital mandates, equips United Laboratories with renewed flexibility for capital management and board continuity heading into FY 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment